Jason Hampl, MD
Family Medicine · Wichita, KSNPI 1669498010
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 673 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,910, 2.6 times the $736 reported in 2019. Among family medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 673 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$807
- Astellas Pharma US Inc$740
- Novo Nordisk$658
- Amgen$645
- AstraZeneca$597
- plus $5K from 48 others
What the payments were for
- Food & beverage$10,077100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,095 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 95 | $100,404 |
| OzempicSemaglutide | 84 | $81,432 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 60 | $73,614 |
| FarxigaDapagliflozin Propanediol | 64 | $69,639 |
| JardianceEmpagliflozin | 66 | $55,230 |
| EliquisApixaban | 86 | $53,482 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 30 | $40,291 |
| XareltoRivaroxaban | 20 | $33,305 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $30,612 |
| JanuviaSitagliptin Phosphate | 19 | $26,590 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $22,942 |
| MyrbetriqMirabegron | 28 | $21,236 |
| TrulicityDulaglutide | 21 | $21,162 |
| Bydureon BciseExenatide Microspheres | 24 | $17,533 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $17,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $658 | $121,723114 claims |
| Lilly USA, LLCMounjaro, Trulicity | $807 | $121,566116 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $144 | $73,61460 claims |
| Boehringer IngelheimJardiance, Glyxambi | $191 | $70,25286 claims |
| AstraZenecaFarxiga | $597 | $69,63964 claims |
| PfizerEliquis, Premarin | $524 | $63,717114 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $503 | $44,78783 claims |
| Johnson & JohnsonXarelto | $328 | $33,30520 claims |
| MerckJanuvia | $140 | $26,59019 claims |
| Astellas Pharma US IncMyrbetriq | $740 | $21,23628 claims |
| AbbVieLinzess, Synthroid | $1,654 | $12,61664 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Wichita
- Mila MeansWichita$241K
- Cole GillenwaterWichita$62K
- Hai TruongWichita$25K
- Deborah OutwaterWichita$25K
- Joseph SackWichita$21K
- Scott StringfieldWichita$20K
- Mark LeikerWichita$20K
- Paul DavisWichita$18K
- Tara NeilWichita$16K
- William SimonWichita$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.